Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of NYX-458 in Healthy Volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 May 2019
Price :
$35
*
At a glance
- Drugs NYX-458 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Aptinyx
- 30 Apr 2019 Results assessing the safety and pharmacokinetics is published in the Aptinyx Media Release
- 14 Aug 2018 According to an Aptinyx media release, trial completion expected in first half of 2019.
- 08 Aug 2018 New trial record